The global chemiluminescence immunoassay market size is expected to reach USD 15.50 billion by 2030, according to a new report. It is expected to expand at a CAGR of 4.6% from 2024 to 2030. The high prevalence of chronic diseases, several advantages of chemiluminescence immunoassay (CLIA) technique, and approval and launch of novel CLIA solutions are anticipated to be the major factors driving the market.
Key players in the market are implementing organic and inorganic growth strategies for the development, launch, and distribution of novel CLIA solutions. For instance, in February 2020, Snibe Diagnostic, a China-based immunoassay manufacturer, received CE marking for its new MAGLUMI 2019-nCoV (SARS-CoV-2) IgM/IgG CLIA kits. In another instance, in January 2018, DiaSorin partnered with Germany-based Qiagen and added Qiagen's QuantiFERON-TB diagnostic test portfolio to its LIAISON family of fully automated chemiluminescence immunoassay analyzers. Such initiatives by major players are anticipated to significantly support the market growth. However, the high setup cost of automated chemiluminescence immunoassay systems is expected to be a major factor hindering the market growth.
Furthermore, the high prevalence of chronic diseases in key regions and increasing awareness regarding these diseases in emerging economies are anticipated to upsurge the demand for novel diagnostic solutions, including chemiluminescence immunoassay. According to the data published by the American Cancer Society, in 2020, an estimated 1.8 million new cases of cancer were diagnosed in the U.S. and around 606,520 people died due to the disease. In addition, as per the data published by the WHO in November 2020, HIV emerged as a major global public health issue and around 37.9 million people around the globe were living with the disease.
This product will be delivered within 1-3 business days.
Key players in the market are implementing organic and inorganic growth strategies for the development, launch, and distribution of novel CLIA solutions. For instance, in February 2020, Snibe Diagnostic, a China-based immunoassay manufacturer, received CE marking for its new MAGLUMI 2019-nCoV (SARS-CoV-2) IgM/IgG CLIA kits. In another instance, in January 2018, DiaSorin partnered with Germany-based Qiagen and added Qiagen's QuantiFERON-TB diagnostic test portfolio to its LIAISON family of fully automated chemiluminescence immunoassay analyzers. Such initiatives by major players are anticipated to significantly support the market growth. However, the high setup cost of automated chemiluminescence immunoassay systems is expected to be a major factor hindering the market growth.
Furthermore, the high prevalence of chronic diseases in key regions and increasing awareness regarding these diseases in emerging economies are anticipated to upsurge the demand for novel diagnostic solutions, including chemiluminescence immunoassay. According to the data published by the American Cancer Society, in 2020, an estimated 1.8 million new cases of cancer were diagnosed in the U.S. and around 606,520 people died due to the disease. In addition, as per the data published by the WHO in November 2020, HIV emerged as a major global public health issue and around 37.9 million people around the globe were living with the disease.
Chemiluminescence Immunoassay Market Report Highlights
- Based on product, consumables dominated the market in 2023 owing to their high demand in therapeutic drug monitoring, endocrinology, and disease diagnosis
- In terms of application, the infectious disease segment held the largest share in 2023 owing to the high prevalence of such diseases and the launch of novel CLIA assays for infectious disease diagnosis
- By end use, in 2020, the hospitals segment accounted for the largest share in 2023 owing to the increasing hospitalizations, along with the rising prevalence of chronic diseases
- In North America, the U.S. held the largest share in 2023 owing to the developed healthcare infrastructure, the high adoption of technologically advanced CLIA systems, and the strong geographical presence of prominent players
- Asia Pacific is expected to expand at the fastest CAGR during the forecast period. The emergence of local players in developing markets, such as India and China, is primarily driving the regional market
This product will be delivered within 1-3 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Chemiluminescence Immunoassay Market Variables, Trends, & Scope
Chapter 4. Chemiluminescence Immunoassay Market: Product Estimates & Trend Analysis
Chapter 5. Chemiluminescence Immunoassay Market: Sample Type Estimates & Trend Analysis
Chapter 6. Chemiluminescence Immunoassay Market: Application Estimates & Trend Analysis
Chapter 7. Chemiluminescence Immunoassay Market: End Use Estimates & Trend Analysis
Chapter 8. Chemiluminescence Immunoassay Market: Regional Estimates & Trend Analysis
Chapter 9. Competitive Landscape
Companies Mentioned
- Abbott Laboratories
- Beckman Coulter Inc.
- DiaSorin S.p.A.
- Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
- F. Hoffmann-La Roche AG
- Siemens Healthineers
- Ortho Clinical Diagnostics
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 150 |
| Published | July 2024 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value ( USD | $ 11.71 Billion |
| Forecasted Market Value ( USD | $ 15.5 Billion |
| Compound Annual Growth Rate | 4.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 7 |
